"Benzaldehydes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that consist of a benzene ring with a formyl group. They occur naturally in the seeds of many fruits and are used as FLAVORING AGENTS and fragrances, as well as precursors in pharmaceutical and plastics manufacturing.
| Descriptor ID |
D001547
|
| MeSH Number(s) |
D02.047.222
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzaldehydes".
Below are MeSH descriptors whose meaning is more specific than "Benzaldehydes".
This graph shows the total number of publications written about "Benzaldehydes" by people in this website by year, and whether "Benzaldehydes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2017 | 3 | 5 | 8 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzaldehydes" by people in Profiles.
-
Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as MPro inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). BMC Res Notes. 2020 Nov 11; 13(1):527.
-
Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion. Transfusion. 2020 12; 60(12):3066-3067.
-
Toxicological Assessment of Intermediates in Natural Attenuation of p-Xylene to Marine Microalgae. Bull Environ Contam Toxicol. 2019 Sep; 103(3):441-446.
-
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. Am Heart J. 2019 02; 208:65-73.
-
Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 06 01; 3(6):473-480.
-
Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. J Am Heart Assoc. 2017 Oct 24; 6(10).
-
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Oct 24; 6(10).
-
Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome. J Am Heart Assoc. 2017 Oct 10; 6(10).
-
Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Sep 14; 6(9).
-
Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2017 Aug 22; 6(8).